User talk:DavidTran

June 2016
Welcome to Wikipedia. Because we have a policy against usernames which give the impression that the account represents a group, organization or website, I have blocked this account; please take a moment to create a new account with a username that represents only yourself as an individual and which complies with our username policy or request a change of username. You should also read our conflict of interest guideline and be aware that promotional editing is not acceptable regardless of the username you choose. If your username does not represent a group, organization or website, you may appeal this username block by adding the text at the bottom of your talk page. You may simply create a new account, but you may prefer to change your username to one that complies with our username policy, so that your past contributions are associated with your new username. If you would prefer to change your username, you may appeal this username block by adding the text at the bottom of your talk page. Thank you. Randykitty (talk) 09:10, 15 June 2016 (UTC)

So what are your editing plans if unblocked? Max Semenik (talk) 01:07, 12 May 2017 (UTC)

So what are your editing plans if unblocked? Max Semenik (talk) 01:07, 12 May 2017 (UTC)
Hello, We would create the page like the following similiar with information from their website:

LuTran Inc.

Type 			       Private Industry			Healthcare Founded 			2016 Headquarters		       Silicon Valley, USA Key people		       David Tran, President Ronald Griffith, Director Products 			Biotechnology Website 			www.lutran.com

LuTran

LuTran Inc. is a pharmaceutical research company headquartered in Silicon Valley with the objective of discovering and developing novel medicines for debilitating viral and neurological diseases: from AIDS through biosafety level 4 viruses, including Ebola hemorrhagic fever and Alzheimer’s.

Contents

1 History

2 Pipeline

3 External Links

History

LuTran was founded in 2016 and is lead by Ronald Griffith, Ph.D., the company’s Director and Chief Science Officer. He is a senior executive with over 30 years of experience in the complete drug development process with a focus on virology and neurological diseases. Ronald has published over 150 patents and publications.

Pipeline

LuTran has multiple compounds in development against the viruses of HIV/AIDS, Ebola, RSV, VZV and Alzheimer’s. Drug discovery efforts focus on improving intrinsic potency through stronger hydrophobic synergies in the target receptor, consequently improving efficacy and enhancing safety through maximizing specific hydrophobic interactions.

External links

Official website